MAP0004, Orally Inhaled Dihydroergotamine for Acute Treatment of Migraine: Efficacy of Early and Late Treatments
Authors:
- Stewart J. TepperSTStewart J. Tepper
- Shashidhar H. KoriSKShashidhar H. Kori
- Peter J. GoadsbyPGPeter J. Goadsby
- Paul K. WinnerPWPaul K. Winner
- Min H. WangMWMin H. Wang
- Stephen D. SilbersteinSSStephen D. Silberstein
- F. Michael CutrerFCF. Michael Cutrer
- 1 October 2011
- journal article
- research article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 86 (10) , 948-955
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- DHE Repression of ATP‐Mediated Sensitization of Trigeminal Ganglion NeuronsHeadache: The Journal of Head and Face Pain, 2010
- Reduced Adverse Event Profile of Orally Inhaled DHE (MAP0004) vs IV DHE: Potential MechanismHeadache: The Journal of Head and Face Pain, 2009
- A Randomized, Double Blind, Placebo‐Controlled Study of MAP0004 in Adult Patients With MigraineHeadache: The Journal of Head and Face Pain, 2009
- Symptoms of Cutaneous Sensitivity Pre-Treatment and Post-Treatment: Results from the Rizatriptan TAME StudiesCephalalgia, 2007
- Efficacy of Rizatriptan 10 mg Administered Early in a Migraine AttackHeadache: The Journal of Head and Face Pain, 2006
- Gastric Stasis in Migraine: More Than Just a Paroxysmal Abnormality During a Migraine AttackHeadache: The Journal of Head and Face Pain, 2006
- The Predictive Value of Abbreviated Migraine Diagnostic CriteriaHeadache: The Journal of Head and Face Pain, 2005
- Eletriptan in the Early Treatment of Acute Migraine: Influence of Pain Intensity and Time of DosingCephalalgia, 2005
- Defeating migraine pain with triptans: A race against the development of cutaneous allodyniaAnnals of Neurology, 2003
- Safety, Tolerability, and Pharmacokinetics of Sumatriptan in Healthy Subjects Following Ascending Single Intranasal Doses and Multiple Intranasal DosesCephalalgia, 1997